Per 25 mg/15 mg FC tab Alogliptin 25 mg, pioglitazone 15 mg. Per 25 mg/30 mg FC tab Alogliptin 25 mg, pioglitazone 30 mg
Indications/Uses
Adjunct to diet & exercise to improve glycemic control in adults w/ type 2 DM in multiple clinical settings when treatment w/ both alogliptin & pioglitazone is appropriate.
Recommended starting dose: 25 mg/15 mg or 25 mg/30 mg once daily. Patients w/ CHF (NYHA class I or II) 25 mg/15 mg once daily. Moderate renal impairment (CrCl ≥30 to <60 mL/min) 12.5 mg/15 mg or 12.5 mg/30 mg once daily. Max: 25 mg/30 mg once daily. In combination w/ gemfibrozil or other strong CYP2C8 inhibitors Max: 25 mg/15 mg once daily.
Liver disease & severe renal impairment. Discontinue use if pancreatitis or serious hypersensitivity develops. History of angioedema to another DPP-4 inhibitor. Patients w/ abnormal liver test. Perform liver test in patients w/ symptoms of liver injury. Edema & risk of CHF. Risk of fracture in female patients. Active or history of bladder cancer. Concomitant use w/ insulin & insulin secretagogues, NSAIDs & coxibs. Perform regular eye exam. Adequate contraception in all premenopausal women. Pregnancy & lactation. Childn. Elderly.
Sign Out
